Jacou, France

Jerome Peyronnet


 

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 11(Granted Patents)


Company Filing History:


Years Active: 2016

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Jerome Peyronnet: Innovator in Pharmaceutical Compounds

Introduction

Jerome Peyronnet is a notable inventor based in Jacou, France. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of viral infections. His innovative work has led to the development of compounds that can potentially improve patient outcomes in liver disorders.

Latest Patents

Jerome Peyronnet holds a patent for "Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections." This patent includes compounds, compositions, and methods specifically designed for treating liver disorders, including HCV infections. The patent outlines various embodiments of nucleoside derivatives that can be administered alone or in combination with other anti-viral agents. The compounds are described according to specific formulas, including pharmaceutically acceptable salts, solvates, tautomeric, or polymorphic forms.

Career Highlights

Throughout his career, Jerome Peyronnet has worked with prominent organizations in the pharmaceutical industry. He has been associated with Idenix Pharmaceuticals, Inc., where he contributed to the development of innovative treatments. Additionally, he has worked at the Centre National De La Recherche Scientifique, furthering his research in the field.

Collaborations

Jerome Peyronnet has collaborated with esteemed colleagues, including Dominique Surleraux and Cyril B Dousson. These partnerships have played a crucial role in advancing his research and patent developments.

Conclusion

Jerome Peyronnet's contributions to pharmaceutical innovations demonstrate his commitment to improving treatments for viral infections. His work continues to influence the field and offers hope for better therapeutic options for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…